RE: Tyk2 Nimbus Celgene17 Aug 2021 18:12
Thoth, what does the final para mean in relation to Sareum?
"As Nimbus and Bristol Myers have remained the furthest along in developing allosteric TYK2 inhibitors, Nimbus says the window for competition “may be closing as BMS gets closer to having its drug approved” because “unless a competitor is already in Phase 2 clinical trials, which no competitor other than Nimbus is, the incentives to stay in or enter the innovation competition will diminish, and likely will disappear, in the next few years.”